Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Buy
70
KRYS Quote, Financials, Valuation and Earnings
Last price:
$261.38
Seasonality move
:
12.7%
Day range:
$252.92 - $267.48
52-week range:
$122.80 - $267.48
Dividend yield:
0%
P/E ratio:
39.21x
P/S ratio:
20.90x
P/B ratio:
6.66x
Volume:
349.9K
Avg. volume:
301K
1-year change:
66.85%
Market cap:
$7.6B
Revenue:
$290.5M
EPS (TTM):
$6.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
$106M | $1.61 | 35.17% | 5.57% | $270.30 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.60 | 98.51% | -58.59% | $490.29 |
|
BLFS
BioLife Solutions, Inc.
|
$24.1M | $0.01 | 5.9% | -98.07% | $32.40 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$141.5M | $0.59 | -0.23% | 4.65% | $34.86 |
|
DXCM
DexCom, Inc.
|
$1.2B | $0.64 | 11.43% | 70.31% | $85.35 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
$261.41 | $270.30 | $7.6B | 39.21x | $0.00 | 0% | 20.90x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$398.29 | $490.29 | $52.6B | 1,656.09x | $0.00 | 0% | 16.34x |
|
BLFS
BioLife Solutions, Inc.
|
$24.86 | $32.40 | $1.2B | -- | $0.00 | 0% | 11.90x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$22.72 | $34.86 | $2.8B | 13.26x | $0.00 | 0% | 4.99x |
|
DXCM
DexCom, Inc.
|
$67.40 | $85.35 | $26.3B | 37.51x | $0.00 | 0% | 6.08x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.28 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.206 | 4.61% | 2.37x |
|
BLFS
BioLife Solutions, Inc.
|
5.52% | 0.467 | 1.69% | 3.31x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.785 | 0.12% | 6.19x |
|
DXCM
DexCom, Inc.
|
48.58% | 1.837 | 9.81% | 1.33x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BLFS
BioLife Solutions, Inc.
|
$17.2M | -$89K | -4.73% | -5.11% | -0.32% | $2.8M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
Krystal Biotech, Inc. vs. Competitors
-
Which has Higher Returns KRYS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 20.1%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About KRYS or ALNY?
Krystal Biotech, Inc. has a consensus price target of $270.30, signalling upside risk potential of 3.4%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $490.29 which suggests that it could grow by 23.1%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.11 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is KRYS or ALNY More Risky?
Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.539%.
-
Which is a Better Dividend Stock KRYS or ALNY?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or ALNY?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Krystal Biotech, Inc.'s net income of $79.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 39.21x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,656.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.90x versus 16.34x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.90x 39.21x $97.8M $79.4M ALNYAlnylam Pharmaceuticals, Inc.16.34x 1,656.09x $1.2B $251.1M
-
Which has Higher Returns KRYS or BLFS?
BioLife Solutions, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 2.21%. Krystal Biotech, Inc.'s return on equity of 19.91% beat BioLife Solutions, Inc.'s return on equity of -5.11%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M -
What do Analysts Say About KRYS or BLFS?
Krystal Biotech, Inc. has a consensus price target of $270.30, signalling upside risk potential of 3.4%. On the other hand BioLife Solutions, Inc. has an analysts' consensus of $32.40 which suggests that it could grow by 30.33%. Given that BioLife Solutions, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe BioLife Solutions, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.11 0 0 BLFSBioLife Solutions, Inc.9 0 0 -
Is KRYS or BLFS More Risky?
Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison BioLife Solutions, Inc. has a beta of 1.929, suggesting its more volatile than the S&P 500 by 92.869%.
-
Which is a Better Dividend Stock KRYS or BLFS?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLife Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. BioLife Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or BLFS?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are larger than BioLife Solutions, Inc. quarterly revenues of $28.1M. Krystal Biotech, Inc.'s net income of $79.4M is higher than BioLife Solutions, Inc.'s net income of $621K. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 39.21x while BioLife Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.90x versus 11.90x for BioLife Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.90x 39.21x $97.8M $79.4M BLFSBioLife Solutions, Inc.11.90x -- $28.1M $621K
-
Which has Higher Returns KRYS or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 35.57%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About KRYS or CPRX?
Krystal Biotech, Inc. has a consensus price target of $270.30, signalling upside risk potential of 3.4%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 53.42%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.11 0 0 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is KRYS or CPRX More Risky?
Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.
-
Which is a Better Dividend Stock KRYS or CPRX?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or CPRX?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Krystal Biotech, Inc.'s net income of $79.4M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 39.21x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.90x versus 4.99x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.90x 39.21x $97.8M $79.4M CPRXCatalyst Pharmaceuticals, Inc.4.99x 13.26x $148.4M $52.8M
-
Which has Higher Returns KRYS or DXCM?
DexCom, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 23.47%. Krystal Biotech, Inc.'s return on equity of 19.91% beat DexCom, Inc.'s return on equity of 30.94%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B DXCMDexCom, Inc.61.8% $0.70 $5.3B -
What do Analysts Say About KRYS or DXCM?
Krystal Biotech, Inc. has a consensus price target of $270.30, signalling upside risk potential of 3.4%. On the other hand DexCom, Inc. has an analysts' consensus of $85.35 which suggests that it could grow by 26.63%. Given that DexCom, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe DexCom, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.11 0 0 DXCMDexCom, Inc.20 4 0 -
Is KRYS or DXCM More Risky?
Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.480, suggesting its more volatile than the S&P 500 by 48.047%.
-
Which is a Better Dividend Stock KRYS or DXCM?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or DXCM?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. Krystal Biotech, Inc.'s net income of $79.4M is lower than DexCom, Inc.'s net income of $283.8M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 39.21x while DexCom, Inc.'s PE ratio is 37.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.90x versus 6.08x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.90x 39.21x $97.8M $79.4M DXCMDexCom, Inc.6.08x 37.51x $1.2B $283.8M
-
Which has Higher Returns KRYS or FOLD?
Amicus Therapeutics, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 10.24%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About KRYS or FOLD?
Krystal Biotech, Inc. has a consensus price target of $270.30, signalling upside risk potential of 3.4%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.88%. Given that Amicus Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KRYSKrystal Biotech, Inc.11 0 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is KRYS or FOLD More Risky?
Krystal Biotech, Inc. has a beta of 0.463, which suggesting that the stock is 53.705% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock KRYS or FOLD?
Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KRYS or FOLD?
Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Krystal Biotech, Inc.'s net income of $79.4M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 39.21x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.90x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KRYSKrystal Biotech, Inc.20.90x 39.21x $97.8M $79.4M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
